Review Article

The Emerging Role of lncRNAs in Spinal Cord Injury

Fei Wang,1 Junzhi Liu,2 Xiunan Wang,3 Jigang Chen,4 Qingjie Kong,5 Baoguo Ye,6 and Zhenxing Li4

1Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, Jilin, China
2Quality Control Department, China-Japan Union Hospital, Jilin University, Changchun, Jilin, China
3Department of Orthopedics, The 964th Hospital of the PLA Joint Logistics Support Force, Changchun, Jilin, China
4Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, China
5Department of Orthopedic Surgery, Spine Center, Changzheng Hospital, Second Military Medical University, Shanghai, China
6Department of Anesthesiology, China-Japan Union Hospital, Jilin University, Changchun, Jilin, China

Correspondence should be addressed to Qingjie Kong; 15900558565@163.com, Baoguo Ye; yebg@jlu.edu.cn, and Zhenxing Li; lizhenxing@smmu.edu.cn

Received 18 June 2019; Revised 5 August 2019; Accepted 13 August 2019; Published 15 October 2019

Academic Editor: Paul Harrison

Copyright © 2019 Fei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Spinal cord injury (SCI) is a highly debilitating disease and is increasingly being recognized as an important global health priority [1]. Approximately half a million people suffer from SCI injured each year [2], and there are estimated to be more than 17000 new cases of SCI annually in the United States [3]. Falls and road traffic accidents are the main contributory factors for SCI [4]. However, nontraumatic conditions, such as insufficient blood flow, inflammatory injuries, spinal tumors, and osteoarthritis, could also lead to SCI [5]. SCI survivors usually face a series of problems including paralysis, sensory dysfunction, neuropathic pain, and other dysfunctions, which pose heavy emotional and economic burdens to individuals, families, and societies [6]. Although the pathophysiological mechanism of SCI is known to be associated with the primary damage caused by initial mechanical injury and secondary damage, the exact mechanism of this disease is still unclear [7]. Secondary damage frequently occurs several minutes or months after SCI and results in persistent neurological impairment. Generally, secondary damage involves vascular dysfunction, inflammation, edema, ischemia, excitotoxicity, free radical production, and restrained apoptotic cell death [8]. Treatment strategies for SCI mainly consist of decompression, stabilization, rehabilitation, pharmacological therapies, cell transplantation, and transplantation of cells with scaffolds; these strategies

1. Introduction

Spinal cord injury (SCI) is one of the most devastating conditions that has been increasingly recognized as an important global health priority [1]. Approximately half a million people suffer from SCI injured each year [2], and there are estimated to be more than 17000 new cases of SCI annually in the United States [3]. Falls and road traffic accidents are the main contributory factors for SCI [4]. However, nontraumatic conditions, such as insufficient blood flow, inflammatory injuries, spinal tumors, and osteoarthritis, could also lead to SCI [5]. SCI survivors usually face a series of problems including paralysis, sensory dysfunction, neuropathic pain, and other dysfunctions, which pose heavy emotional and economic burdens to individuals, families, and societies [6]. Although the pathophysiological mechanism of SCI is known to be associated with the primary damage caused by initial mechanical injury and secondary damage, the exact mechanism of this disease is still unclear [7]. Secondary damage frequently occurs several minutes or months after SCI and results in persistent neurological impairment. Generally, secondary damage involves vascular dysfunction, inflammation, edema, ischemia, excitotoxicity, free radical production, and restrained apoptotic cell death [8]. Treatment strategies for SCI mainly consist of decompression, stabilization, rehabilitation, pharmacological therapies, cell transplantation, and transplantation of cells with scaffolds; these strategies
vary according to the stage of the disease [8, 9]. However, there is still a lack of prompt strategies for preventing the secondary injury associated with SCI and effective treatment measures for the satisfactory recovery from SCI.

With the development of microarray and high-throughput sequence technologies, many differentially expressed genes including coding RNAs and noncoding RNAs have gradually been identified to be involved in various diseases during the past several years. Noncoding RNA genes, such as ribosomal RNAs, transfer RNAs, small nuclear RNAs, microRNAs (miRNAs), and long noncoding RNAs (lncRNAs), have been shown to exist in human and rodent genomes. MiRNAs have been recognized to be differentially expressed after SCI and may be novel biomarkers for the diagnosis, treatment, and prognosis of such injuries [10]. For example, Hachisuka et al. have analyzed candidate miRNAs whose expression levels were altered in the serum relative to the severity of SCI and identified that the serum miR-9*, miR-219, and miR-384-5p levels may be promising biomarkers for predicting the severity of SCI [11]. LncRNAs, which are a large type of noncoding RNAs, have been emerging as important regulators of multiple disease processes [12]. However, the functional significance of lncRNAs in SCI and the mechanisms underlying their involvement are lesser known compared with those of miRNAs. LncRNAs constitute the largest portion of mammalian noncoding RNAs [13]. Once regarded as transcriptional noises, increasing evidences have demonstrated that lncRNAs have multiple domains that can bind to DNA, RNA, and proteins, modify the chromatin status, regulate transcription and translation, and ultimately affect gene expression [14]. Although the functions of lncRNAs have not yet been completely decoded, studies have shown that they play different roles in cell proliferation, survival, and migration as well as in maintaining genomic stability via guidance, bait, scaffold, and signaling molecules [15, 16]. In this review, we have summarized the current knowledge about the roles of lncRNAs associated with SCI, which would help in the search for new therapeutic strategies against SCI.

2. LncRNAs and Neurological Diseases

LncRNAs are highly expressed in the central nervous system (CNS) [17]. Their aberrant expression has been confirmed to be related to traumatic brain injury (TBI), neurodegenerative diseases, ischemic cerebrovascular diseases, gliomas, and other neurological diseases. Firstly, lncRNAs have been demonstrated to be significantly expressed following TBI [18, 19]. The altered expression of lncRNAs may be related to their biological functions following TBI, such as inflammatory response, metabolism, and apoptosis [20]. It is worth mentioning that lncRNAs could act as competing endogenous RNAs (ceRNAs) to regulate coding RNA transcripts by sponging miRNA [21]. For example, Yu et al. have demonstrated that the transcript of the lncRNA Gm4419 could play the role of a sponge for miR-466l and promote the traumatic injury-induced apoptosis of astrocytes by upregulating the expression of the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) [22]. Secondly, genome-wide association studies and comparative transcriptome analysis have indicated that the dysregulation of, or mutations in, lncRNA gene loci is associated with Alzheimer’s disease (AD) [23], Parkinson’s disease (PD) [24], and other neurodegenerative diseases [25]. For example, the level of the lncRNA BACE1 in the cytoplasm of patients with AD has been reported to be significantly higher than that in the control patients. Its upregulation can be used as a new biomarker for the diagnosis of AD [26]. Previous studies have found that the mutations of the UCHL1 gene and oxidative inactivation of the Uch1l protein were associated with familial PD [27]. The lncRNA Uch1l-AS has been shown to increase the protein synthesis of UCHL1 at the posttranscriptional level; this depends on the combined activities of two domains, the 50 antisense region, which confers specificity for the sense target gene, and the embedded repetitive short interspersed nuclear element of B3 subclass (SINEB2) element, which makes the protein synthesis activation domain available [28]. Thirdly, Zhang et al. have found that the knockout of the lncRNA Malat1 in a mouse model of oxygen and glucose deprivation (OGD) led to a significant increase in the expression of proapoptotic factors and proinflammatory cytokines, indicating that Malat1 may have a protective role against ischemic stroke [29]. Furthermore, a recent study has demonstrated that the lncRNA SNHG6 could function as a ceRNA to regulate neuronal cell apoptosis by modulating miR-181c-5p and Bcl-2-interacting mediator of cell death signaling in ischemic stroke [30]. Lastly, the significance of lncRNAs involved in glioma has begun to be revealed. AXL, which is a receptor tyrosine kinase, has been reported to be overexpressed in human glioma and associated with poor prognosis of glioma patients [31]. Yan et al. have proved that the lncRNA LINCO0526 could repress glioma progression by forming a double negative feedback loop with AXL [32]. In addition, MALAT1 has also been considered to decrease the sensitivity of resistant glioblastoma to chemotherapy [33]. Although many studies have recently reported the potential value of lncRNAs in neurological diseases, research regarding this topic is still in its infancy, especially with regards to their roles in SCI.

3. LncRNAs in SCI

3.1. LncRNA Expression Profiles in Traumatic SCI

LncRNA microarrays, RNA sequencing (RNA-Seq), and bioinformatics analysis are commonly used to explore the expression of lncRNAs and delineate their molecular functions. To date, in particular, six studies have reported the alterations of lncRNAs in mice or rats after traumatic SCI (Table 1). In 2015, for the first time, Wang et al. performed the screening of lncRNA expression changes after spinal cord contusion in rats at one, four, and seven days after injury [34]; seven lncRNAs were found to be differentially expressed, and RGD1559747 (named as lncSCI1) showed a significant downregulation at all time points. To better understand the molecular mechanisms of SCI and look for an early therapeutic time window, Zhou et al. have
investigated the lncRNA and messenger RNA (mRNA) expression in the immediate phase after SCI [35]. A total of 772 lncRNAs and 992 mRNAs were identified two hours after the injury. The toll-like-receptor (TLR) signaling pathway, p53 signaling pathway, MAPK signaling pathway, and Jak–STAT signaling pathway have been found to be mainly associated with the differentially expressed genes. Alterations of lncRNAs at the acute stages of SCI have also been studied. Ding et al. have detected the expression patterns and levels of lncRNAs and mRNAs at five continuous time points in a mouse model of spinal cord contusion [36]. In this study, few changes in the lncRNA expression levels were observed one day after the injury. However, these changes peaked one week after SCI and subsequently declined until three weeks after SCI. Gene ontology (GO) analysis showed that the differential lncRNAs were mainly associated with transport, cell adhesion, ion transport, and metabolic processes. The Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis indicated that the neuroactive ligand-receptor interaction, the PI3K-Akt signaling pathway, and focal adhesions may be involved in the pathology of SCI. Furthermore, 264 lncRNAs and 949 mRNAs have been utilized to construct a dynamic lncRNA-mRNA network to elucidate the interactions between the lncRNAs and mRNAs and predict the key modulators. Shi et al. have explored the expression of lncRNAs and mRNAs in a rat model of SCI [37]; a total of 3,193 lncRNAs and 4,308 mRNAs have been found to be differentially expressed two days after SCI. They also identified ten core genes such as IL6, TOP2A, and CDK1 using a protein-protein interaction (PPI) network. Similarly, Wang et al. have profiled the expression of noncoding RNAs and mRNAs of mice using a standard Allen’s weight-drop model of SCI [38]. A total of 458 lncRNAs were identified to be differentially expressed, in addition to 498 circRNAs, 458 lncRNAs, 155 miRNAs, and 1203 mRNAs. Coexpression network analyses suggested that lncRNAs and other noncoding RNAs may play crucial roles in the acute stage of SCI, based on the patterns of the regulation of ceRNAs.

Contrary to the research in the immediate and acute stages of SCI, Duran et al. have investigated the significant alterations of lncRNAs in the subchronic and chronic stages of SCI in rats [39]. The numbers of differentially expressed lncRNAs at the one-month, three-month, and six-month time points were 137, 239, and 179, respectively. The results showed that a high level of transcriptional abnormalities persistently existed in the subchronic and chronic stages, and the altered genes were related to several pathways such as immune and inflammatory responses, as well as gliosis. This study identified a new series of lncRNAs that may potentially be involved in the progression of SCI.

The above studies have shown the dynamic lncRNA expression profiles at different stages of SCI, and these profiles were associated with the secondary injury-related pathological changes. These results provided preliminary insights into the stage-specific regulation of lncRNAs during SCI. However, further experimental verification, such as the assessment of the effects of the knockdown or overexpression of the selected lncRNAs on SCI-induced pathological changes or functional recovery at the epigenetic, transcriptional, or posttranscriptional levels, is required to confirm these aspects. Additionally, the interactions between the differentially expressed lncRNAs in SCI are yet to be discovered.

### 3.2. lncRNAs in the Pathophysiological Process of SCI

SCI, which poses a major challenge in the field of neurotrauma, triggers complex pathophysiological processes [40]. Inflammation is considered the most common phenomenon occurring immediately during the secondary injury stage of SCI, which is concomitant with the activation of microglia, T cells, and astrocytes [7, 41]. A previous study has shown that Krüppel-like factor 4 (KLF4) was involved in SCI and could regulate microglial activation and subsequent neuroinflammation [42]. In a rat model of SCI, Jiang and Zhang have observed that the lncRNA SNHG5 and KLF4 were highly expressed during SCI [43]. They also have proved that KLF4 was a direct target for SNHG5. SNHG5 was further demonstrated to increase the viability of astrocytes and microglia via the upregulation of KLF4 and promote the process of SCI.

<table>
<thead>
<tr>
<th>Published year</th>
<th>Animal</th>
<th>Model</th>
<th>Injury sites</th>
<th>Time point</th>
<th>Methods</th>
<th>Differentially expressed lncRNAs</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>Rats</td>
<td>Contusion SCI</td>
<td>T10</td>
<td>1, 4, and 7 d</td>
<td>RNA sequencing</td>
<td>7 (lincSCR1 constantly downregulated)</td>
<td>Wang et al. [34]</td>
</tr>
<tr>
<td>2016</td>
<td>Mice</td>
<td>Contusion SCI</td>
<td>T10</td>
<td>1 d, 3 d, 1 w, and 3 w</td>
<td>Microarray</td>
<td>Few changes in 1 d, peaked in 1 w and declined in 3 w</td>
<td>Ding et al. [36]</td>
</tr>
<tr>
<td>2016</td>
<td>Rats</td>
<td>SCI</td>
<td>T9</td>
<td>1 m, 3 m and 6 m</td>
<td>RNA sequencing</td>
<td>1 m: 137 (120 up, 17 down); 3 m: 239 (162 up, 77 down); 6 m: 179 (125 up, 54 down)</td>
<td>Duran et al. [39]</td>
</tr>
<tr>
<td>2017</td>
<td>Rats</td>
<td>Contusion SCI</td>
<td>T10</td>
<td>2 h</td>
<td>Microarray</td>
<td>772 (528 up, 244 down)</td>
<td>Zhou et al. [35]</td>
</tr>
<tr>
<td>2018</td>
<td>Rats</td>
<td>Contusion SCI</td>
<td>T10</td>
<td>2 d</td>
<td>Microarray</td>
<td>3193 (1332 up, 1,861 down)</td>
<td>Shi et al. [37]</td>
</tr>
<tr>
<td>2019</td>
<td>Mice</td>
<td>Standard Allen’s weight-drop model of SCI</td>
<td>T8-10</td>
<td>3 d</td>
<td>RNA sequencing</td>
<td>458 (356 up, 93 down)</td>
<td>Wang et al. [38]</td>
</tr>
</tbody>
</table>

d, day; h, hour; w, week; lncRNAs, long noncoding RNAs; m: month; SCI, spinal cord injury; T, thoracic level.
Zhou et al. have also detected that the significant increase in the expression of the lncRNA MALAT1 was accompanied by the activation of the 1xβ kinase β-nuclear factor-kappa B (IKKβ/NF-κB) signaling pathway and increased expression of proinflammatory cytokines [44]. IKKβ is a key catalytic subunit of the IKK complex and plays a crucial role in the activation of nuclear factor-kappa B (NF-κB), which is a major initiator of inflammation [45]. In the spinal cord, the inhibition of NF-κB activity prevents immune cells from expressing certain proinflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), or IL-1β. Downregulation of miR-199b has been demonstrated to promote the process of acute SCI via the IKKβ-NF-κB signaling pathway-mediated activation of microglial cells [46]. Additionally, it has been confirmed that MALAT1 promoted the inflammatory response of microglia following SCI via the modulation of the miR-199b/IKKβ-NF-κB signaling pathway. In addition, in a rat model of spinal cord ischemia reperfusion (IR) injury, Jia et al. have found that the downregulation of the lncRNA TUG1 inhibited Toll-like receptor 4 (TLR4) signaling pathway-mediated inflammatory damage via the suppression of TLR4 interactor with leucine-rich repeats (TRIL) expression [47]. The TLR4-mediated NF-κB signaling pathway is involved in spinal cord IR injury. TLR4 inhibition reduces the release of inflammatory cytokines after spinal cord IR injury [48]. TRIL, a receptor accessory protein of TLR4, plays an important role in regulating the activation of TLR4 and the release of its downstream inflammatory cytokine IL-1β [49]. Therefore, the inhibition of TLR4 by the lncRNA TUG1 would reduce the release of inflammatory cytokines after spinal cord IR injury [48]. Moreover, in a rat model of compressive SCI, Yu et al. have found that the overexpression of the lncRNA TUSC7 could have inhibited microglial activation and the expression of inflammatory factors in microglial cells by regulating the expression of peroxisome proliferator-activated receptor gamma through miR-449a [50]. Therefore, these studies provided valuable insights into the role of lncRNAs in the neuroinflammatory processes associated with traumatic or nontraumatic SCI.

Neuronal apoptosis is also an important feature in the pathophysiology of SCI [51]. Gu et al. have evaluated the roles of the lncRNA X-inactive specific transcript (XIST) in the pathogenesis of SCI [52]. They have found that the downregulation of XIST contributed to the suppression of neuronal apoptosis and the protective effects of XIST knockdown relied on a sponge for miR-494, which ultimately regulated the phosphatase and tensin homolog deleted on chromosome ten (PTEN)/phosphoinositide 3-0H kinase (PI3K)/AKT signaling pathway. More specifically, PTEN can restrict the binding of AKT to plasma membranes, thereby decreasing its activity [53]. The PI3K/AKT signaling pathway is a major determinant of the control of diverse cellular processes, including SCI [54]. PI3K activates phosphorylation and results in the activation of AKT. AKT has important downstream effects such as localizing FOXO in the cytoplasm, activating CREB [55], and activating mTOR, subsequently affecting the transcription of either p70 or 4EBP1 [56]. This pathway is crucial in facilitating both the growth and proliferation of adult neural cells. Analogously, the knockdown of the lncRNA brain-derived neurotrophic factor antisense (lncRNA BDNF-AS) has been identified to suppress neuronal cell apoptosis by sponging miR-130b-5p and targeting gene (PRDI-BF1 and RIZ) domain protein 5 [57]. Different from the protective effects caused by the knockdown of some specific lncRNAs, the overexpression of the lncRNA Map2k4 and TCTN2 has been found to protect neurons from apoptosis after SCI by regulating the miR-199a/FGF1 pathway and enhancing cell autophagy, respectively [58, 59]. FGF1 is a multifunctional peptide growth factor and is mainly distributed in the CNS [60]. The FGF1 pathway is essential for the survival of neurons and plays an important role in CNS injury repair. Although further researches are needed to verify the therapeutic value of lncRNAs, these studies indicate some potential treatment targets for SCI.

Oxidative stress generally proceeds after the occurrence of SCI; it would contribute to tissue injury and cell apoptosis during the secondary injury stage of SCI [61, 62]. In some researches [63–66], pheochromocytoma (PC-12) cells cultured under a condition of hydrogen peroxide (H2O2) stimulation have been used as a common in vitro cell-damage model to simulate secondary oxidative stress changes after SCI. In the study by Liu et al., the overexpression of the lncRNA small nuclear RNA host gene 16 (SNHG16) has been shown to alleviate H2O2-induced cell injury by regulating the expression of miR-423-5p in PC-12 cells [64]. Similar to the protective effects of SNHG16, suppression of the lncRNA ANRIL may aggravate H2O2-induced injury in PC-12 cells by targeting miR-125a [65]. However, the lncRNA Sox2 overlapping transcript (Sox2ot) might enhance oxidative stress, given the observation that the downregulation of Sox2ot has been shown to alleviate H2O2 injury in PC-12 cells by regulating the miR-211-myeloid cell leukemia-1 isoform2 axis [66]. The different roles of lncRNAs in the pathophysiological process of SCI are summarized in Figure 1.

### 3.3. LncRNAs in the Complications of SCI

Neuropathic pain (NP) can develop after nerve injuries and is mostly defined as pain associated with a lesion or disease of the somatosensory nervous system [67, 68]. Approximately 30–50% of SCI patients have NP, which is one of the most common complications of SCI [69]. Refractory diseases such as NP are a worldwide health problem. Functional roles of lncRNAs and their potential mechanisms in NP have been reviewed in the previous literatures [70, 71]. The levels of lncRNAs have been reported to be significantly altered in the spinal cord of an animal model of spared nerve injury [72, 73]. The expression profiling of lncRNAs in dorsal root ganglia has also revealed that the expression of lncRNAs is dysregulated after nerve injury [74]. GO analysis has shown that several lncRNAs were enriched for sensory and neuronal processes [75]. Additionally, Hu et al. have reported that the silencing of the lncRNA PKIA-ASI could attenuate NP via the downregulation of CDK6 expression in the spinal cord tissues of a rat model of spinal nerve ligation [76]. In a rat...
model of chronic constriction injury, the lncRNAs "NEAT1" and "XIST" have also been identified to contribute to the development of NP by targeting the "miR-381/HMGB1" axis or regulating "miR-150" and "ZEB1", respectively [77, 78]. In summary, extensive genomic evidence has been provided for the novel potential targets of lncRNAs for the treatment of NP.

3.4. LncRNAs in the Treatment of SCI. In recent years, stem cells have gained plenty of attentions due to their immense potential of self-renewal and generating cells from glial and neuronal lineages [79]. Neural stem cells have been proposed as a promising therapeutic method for treating SCI [80]. However, the clinical transformation and application of stem cells for the treatment of SCI still have a long way to go. Fortunately, recent studies have indicated that lncRNAs play vital roles in the self-renewal and determination of the fate of stem cells [81, 82]. In particular, the lncRNA human urothelial carcinoma associated 1 ("UCA1") has been demonstrated to regulate the proliferation and differentiation of neural stem cells by controlling the "miR-1/Hes1" expression...
This study implicated important roles of IncRNAs in neural stem cells for the repair of SCI. Hydrogen sulfide has been recognized as an important neuromodulator and neuroprotective agent for SCI [84, 85]. However, the mechanisms underlying the protective effects of hydrogen sulfide against SCI are still unclear. Liu et al. have found that the expression of the lncRNA cancer susceptibility candidate 7 (CasC7) was significantly reduced in rats with spinal cord I/R injury and in vitro [86]. However, hydrogen sulfide preprocessing has been shown to upregulate CasC7 and downregulate miR-30c in vitro. Silencing of CasC7 could upregulate miR-30c expression and promote cell apoptosis. Further, this study also demonstrated that hydrogen sulfide could upregulate CasC7 expression and subsequently and protect rats from spinal cord I/R injury. This study presents a novel direction in the search for drug targets for the treatment of SCI.

3.5. MiRNAs and SCI. Since many IncRNAs exert their functions via regulating miRNAs, the relationship between miRNAs and SCI should be investigated to identify more targeted therapies for SCI. MiRNAs are endogenous small noncoding RNAs composed of ~22 nt nucleotides that can function as gene regulators by binding to the 3′-untranslated region (UTR) of target miRNAs [87]. A great number of miRNAs have been found in the spinal cord, and some miRNAs are specialized for specific cell types [88, 89]. Microarray studies have indicated that the expression of miRNAs was significantly altered after SCI, and these alterations had important effects on the pathogenesis of secondary SCI [88, 90]. Bcl-2 family proteins, including proapoptotic BH3-only family members and myeloid cell leukemia sequence-1 (Mcl-1), can mediate neuronal apoptosis. MiR-20a and miR-29b have been confirmed to target the Mcl-1 and BH3-only family genes, respectively, and together, they regulate SCI-induced apoptosis [91, 92]. MiR-21 expression has been shown to be upregulated following SCI, and miR-21 has been demonstrated to participate in the regulation of astrocytic and glial hypertrophy after SCI [93]. The miR-223 expression has been shown to have increased after SCI; it may regulate the activity of neutrophils and macrophages in the secondary damage phase of SCI [94]. Furthermore, miRNAs may also be used as biomarkers for diagnostic and prognostic purposes with regards to SCI [95]. Due to multiple evidences of the roles of miRNAs in SCI, a systematic analysis of the existing important miRNAs and the prediction of potential targeted IncRNAs would help elucidate the regulatory mechanisms involved following SCI.

3.6. Future Perspectives and Conclusion. IncRNAs have received an increasing amount of attention for their ability to modulate transcriptional regulation in neurological diseases. Several studies have reported the roles of IncRNAs after SCI. However, research regarding this aspect is currently in its infancy, and the mechanisms underlying their role in SCI are yet to be elucidated. Firstly, although alterations in IncRNA expression have been reported in SCI, more researches focused on the multidimensional interactions of IncRNAs that are not just limited to their functions as ceRNAs, and more comprehensive analyses of their expression profiles, such as analyses involving their coupling with circular RNAs, are needed. Secondly, alterations in the expression levels of IncRNAs in blood samples after SCI have not yet been studied. Such IncRNAs with abnormal findings in blood tests may serve as potential novel biomarkers. Thirdly, although the roles of several IncRNAs in the pathophysiological process and treatment of SCI have been explored, more profound researches are relatively scarce, and the validation of their functions is not powerful enough.

To better understand the roles of IncRNAs in SCI, we have several suggestions for potential further studies. As a series of IncRNAs have been identified following SCI, their respective functions could be determined by investigating which molecules (DNA, RNA, or proteins) and these IncRNAs may potentially interact with. Some technologies have been developed to validate the molecular mechanisms of IncRNAs. For example, RNA antisense purification (RAP), chromatin isolation by RNA purification-sequencing (ChIRP), and capture hybridization analysis of RNA targets (CHART) are popular methods to identify target genes of IncRNAs. RNA pull-down assays, RNA immunoprecipitation followed by high-throughput sequencing (RIP-seq), and RAP-mass spectrometry (RAP-MS) are also commonly used to explore the interactions between IncRNAs and proteins [96]. In addition, the recent single-cell RNA-Seq technique provides a new opportunity for explaining the roles of IncRNAs at the single-cell resolution to understand their cell-specific mechanisms.

In conclusion, IncRNAs have been recognized to play multiple complex roles in SCI and may subsequently serve as promising biomarkers for the diagnosis, evaluation, treatment, and prognosis of this debilitating disease. Future studies focused on the detailed mechanisms, and functional roles of IncRNAs are required to develop targeted therapies for SCI.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this work.

Acknowledgments
This study was funded by the special fund for the Key Laboratory of Science and Technology Department of Jilin Province (20190201282J).

References


